Catalyst Capital Advisors’s Transmedics TMDX Stock Holding History

Catalyst Capital Advisors’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$868K	Buy	13,065 +7,710	+144%	+$653K	0.01%	147
2026 Q1	$532K	Sell	5,355 -1,220	-19%	-$159K	0.01%	167
2025 Q4	$800K	Sell	6,575 -300	-4%	-$37.6K	0.02%	153
2025 Q3	$771K	Buy	6,875 +3,725	+118%	+$436K	0.02%	153
2025 Q2	$422K	Hold	3,150	–	–	0.01%	191
2025 Q1	$212K	Sell	3,150 -1,650	-34%	-$113K	﹤0.01%	233
2024 Q4	$299K	Hold	4,800	–	–	0.01%	211
2024 Q3	$754K	Sell	4,800 -1,725	-26%	-$266K	0.02%	165
2024 Q2	$983K	Sell	6,525 -975	-13%	-$117K	0.02%	150
2024 Q1	$555K	Buy	+7,500	New	+$618K	0.01%	176
2019 Q3	–	Sell	-435	Closed	-$13K	–	478
2019 Q2	$13K	Buy	+435	New	+$11.9K	﹤0.01%	299

Other funds holding TMDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Catalyst Capital Advisors's TMDX Position: Q2 2026 in Review

Catalyst Capital Advisors increased its Transmedics (TMDX) stake by 144% in Q2 2026, buying an estimated $653K and bringing the position to 13,065 shares worth $868K. The position accounts for 0.01% of the portfolio, ranked #147.

Catalyst Capital Advisors first reported a position in TMDX in Q2 2019 and has held it in 11 quarters since. The position peaked at $983K in Q2 2024. 374 funds tracked by Wall St. Rank hold TMDX as of Q2 2026.

Catalyst Capital Advisors held 13,065 shares of Transmedics worth $868K as of Q2 2026.
Catalyst Capital Advisors bought 7,710 Transmedics shares in Q2 2026, an estimated $653K.
Transmedics made up 0.01% of Catalyst Capital Advisors's portfolio in Q2 2026, its #147 holding.
Catalyst Capital Advisors first reported a position in Transmedics in Q2 2019 and has held it in 11 quarters since.
Catalyst Capital Advisors's Transmedics position peaked at $983K in Q2 2024.
374 funds tracked by Wall St. Rank held Transmedics as of Q2 2026.

Based on Catalyst Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.